Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.56 |
| ▸ | CDK4 | P11802 | 8/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.56 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 11/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.51 |
| ▸ | CDK1 | P06493 | 8/20 | 0.50 |
| ▸ | CDK7 | P50613 | 7/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.50 |
| ▸ | CCNH | P51946 | 3/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 5/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.49 |
| ▸ | WEE1 | P30291 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893280 | 0.89 | CDK2 (0.57) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL1890923 | 0.83 | PIK3CG (0.60) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL22684851 | 0.82 | CDK2 (0.56) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL23068648 | 0.82 | CDK2 (0.55) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL23068687 | 0.81 | SMN1; SMN2 (0.59) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL23068667 | 0.81 | CDK2 (0.55) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL29629247 | 0.80 | CDK2 (0.51) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL22684844 | 0.80 | CDK2 (0.51) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL23068638 | 0.79 | CDK2 (0.57) | CDK2CDK4CCNA2PLK1CDK9 | |
| SCHEMBL22684849 | 0.79 | CDK2 (0.56) | CDK2CDK4CCNA2PLK1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | CDK8, CDK18, CDK9 | CDK2 8/4885CDK4 13/4885CCNA2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.